148 related articles for article (PubMed ID: 32464648)
1. Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN.
Ledwoch J; Sievert K; Boersma LVA; Bergmann MW; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts TR; Mazzone P; Foley D; Grygier M; De Potter T; Sievert H;
Europace; 2020 Jul; 22(7):1036-1043. PubMed ID: 32464648
[TBL] [Abstract][Full Text] [Related]
2. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
[TBL] [Abstract][Full Text] [Related]
3. Looking for optimal antithrombotic strategy after transcatheter left atrial appendage occlusion: a real-world comparison of different antiplatelet regimens.
Vignali L; Gurgoglione FL; Barocelli F; Cattabiani MA; Solinas E; Maini A; Tadonio I; Benatti G; Pelà G; Coli S; Ardissino D; Niccoli G
Int J Cardiol; 2023 Jan; 371():92-99. PubMed ID: 36181948
[TBL] [Abstract][Full Text] [Related]
4. True Efficacy of LAA Closure: Patient Outcomes on Long-term Single-Antiplatelet or No Therapy: Insights From the EWOLUTION Registry.
Paitazoglou C; Bergmann MW; Ince H; Kische S; Romanov A; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Vireca E; Wohlmuth P; Boersma L;
J Invasive Cardiol; 2022 May; 34(5):E348-E355. PubMed ID: 35501111
[TBL] [Abstract][Full Text] [Related]
5. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
[TBL] [Abstract][Full Text] [Related]
6. Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.
Carvalho PEP; Gewehr DM; Miyawaki IA; Nogueira A; Felix N; Garot P; Darmon A; Mazzone P; Preda A; Nascimento BR; Kubrusly LF; Cardoso R
J Am Coll Cardiol; 2023 Oct; 82(18):1765-1773. PubMed ID: 37611779
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study).
Flores-Umanzor EJ; Cepas-Guillen PL; Arzamendi D; Cruz-González I; Regueiro A; Freixa X
J Interv Card Electrophysiol; 2020 Nov; 59(2):471-477. PubMed ID: 32986176
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation versus antiplatelet therapy after percutaneous left atrial appendage closure-subanalysis from the multicenter LAARGE registry.
Ledwoch J; Staubach S; Akin I; Ince H; Zeymer U; Pleger S; Sievert H; Hochadel M; Senges J; Lewalter T; Brachmann J; Mudra H
J Interv Card Electrophysiol; 2022 Aug; 64(2):489-496. PubMed ID: 34686928
[TBL] [Abstract][Full Text] [Related]
9. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage.
Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Mazzone P; Foley D; Grygier M; Sievert H; De Potter T; Vireca E; Stein K; Bergmann MW;
Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e006841. PubMed ID: 30939908
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry.
Bergmann MW; Betts TR; Sievert H; Schmidt B; Pokushalov E; Kische S; Schmitz T; Meincke F; Stein KM; Boersma LVA; Ince H
EuroIntervention; 2017 Sep; 13(7):877-884. PubMed ID: 28606886
[TBL] [Abstract][Full Text] [Related]
11. Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion.
Della Rocca DG; Magnocavallo M; Di Biase L; Mohanty S; Trivedi C; Tarantino N; Gianni C; Lavalle C; Van Niekerk CJ; Romero J; Briceño DF; Bassiouny M; Al-Ahmad A; Burkhardt JD; Natale VN; Gallinghouse GJ; Del Prete A; Forleo GB; Sanchez J; Lakkireddy D; Horton RP; Gibson DN; Natale A
JACC Cardiovasc Interv; 2021 Nov; 14(21):2353-2364. PubMed ID: 34656496
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Foley D; Sievert H; Mazzone P; De Potter T; Vireca E; Stein K; Bergmann MW;
Heart Rhythm; 2017 Sep; 14(9):1302-1308. PubMed ID: 28577840
[TBL] [Abstract][Full Text] [Related]
13. Short-term antiplatelet versus anticoagulant therapy after left atrial appendage closure: a systematic review and meta-analysis.
Zhou Q; Liu X; Gu ZC; Yang X; Huang XH; Wu YZ; Tao YY; Wei M
J Thromb Thrombolysis; 2024 Feb; 57(2):194-203. PubMed ID: 38180590
[TBL] [Abstract][Full Text] [Related]
14. Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure.
Saw J; Fahmy P; Azzalini L; Marquis JF; Hibbert B; Morillo C; Carrizo A; Ibrahim R
J Cardiovasc Electrophysiol; 2017 Apr; 28(4):396-401. PubMed ID: 28128883
[TBL] [Abstract][Full Text] [Related]
15. Residual stroke risk after left atrial appendage closure in patients with prior oral anticoagulation failure.
Pracoń R; Zieliński K; Bangalore S; Konka M; Kruk M; Kępka C; Trochimiuk P; Dębski M; Przyłuski J; Kaczmarska E; Dzielińska Z; Kurowski A; Witkowski A; Demkow M
Int J Cardiol; 2022 May; 354():17-21. PubMed ID: 35219744
[TBL] [Abstract][Full Text] [Related]
16. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic Regimen After Percutaneous Left Atrial Appendage Closure - A Real-World Study.
Ryuzaki S; Kondo Y; Nakano M; Nakano M; Kajiyama T; Ito R; Kitagawa M; Sugawara M; Chiba T; Yoshino Y; Kobayashi Y
Circ J; 2023 Nov; 87(12):1820-1827. PubMed ID: 37344404
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
[TBL] [Abstract][Full Text] [Related]
19. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
